Valeant Pharmaceuticals Files Long Overdue Financial Results, Curing Default Risk

Valeant's 10-K filing may usher in a process of recovery after months of turmoil, but it also gives new insight into extent of the drugmaker's woes stemming from operational weaknesses, poor disclosure, and regulatory investigations.